The new legislation in the UK in 2018 created a fundamental change in access to medical marijuana. The government at the time, led by Theresa May, allowed the National Health Service and private providers to prescribe cannabis-based medical products. This legal change brought hope for patients suffering from pain and chronic illnesses.
Patient Experience: From Prescription to Use
Currently, the NHS only prescribes medical marijuana for a few specific conditions such as severe and rare types of epilepsy and muscle spasms caused by multiple sclerosis. However, in reality, most prescriptions for medical marijuana are made through private providers. This raises questions about access and equity in the healthcare system. Can real patients access these services, or are only those with greater financial resources benefiting from this opportunity?
Challenges Facing Patients
Many patients seeking a prescription for medical marijuana through private providers face multiple challenges. High consultation and treatment costs may prevent some from receiving these services. Meanwhile, other patients being treated through the NHS face fewer restrictions. This difference in access to services can create serious inequalities in the healthcare system.
Given this situation, the question arises whether all patients can truly take advantage of this opportunity, or only a limited number of those with greater financial means can access this treatment? This issue requires further investigation, and the voices of patients must be heard.
